Mechanisms of β-lactam resistance among Pseudomonas aeruginosa

Current Pharmaceutical Design

Volumn 19, Issue 2, 2013, Pages 209-222

  Wolter, Daniel J ^a   Lister, Philip D ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pseudomonas aeruginosa; Resistance; lactam

Indexed keywords

BETA LACTAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLAVULANIC ACID; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; TICARCILLIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BIOFILM; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 84877930877     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804070311     Document Type: Review

References (216)

1. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, ed. eds., Principles and Practice of Infectious Diseases. Churchill Livingstone: New York 1995; pp 1980-2003.
2. Pitt TL. Pseudomonas, Burkholderia, and Related Genera. In: Duerden BI, ed. eds., Microbiology and Microbial Infections. Oxford University Press Inc: New York City 1998; pp. 1109-38.
3. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Dolan R, Bennett JE, ed. eds., Principles and Practices of Infectious Diseases. Churchill Livingstone: New York 1995; pp. 1820-2003.
4. Harris AA, Goodman L, Levin S. community-acquired Pseudomonas aeruginosa pneumonia associated with the use of a home humidifier. West J Med 1984; 141: 521-3.
5. Morrison AJ, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev. Infect. Dis 1984; 6 (Suppl 3): S627-42.
6. Blanc DS, Petignat C, Janin B, Bille J, Fancioli P. Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study. Clin Microbiol Infect 1998; 4: 242-7.
7. Thuong M, Arvaniti K, Ruimy R, et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J Hosp Infect 2003; 53: 274-82.
8. Valles J, Mariscal D, Cortes P, et al. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilatorassociated pneumonia. Intensive Care Med. 2004; 30: 1768-75.
9. Ohara T, Itoh K. Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract. Intern. Med. 2003; 42: 1072-6.
10. Erol S, Altoparlak U, Akcay MN, Celebi F, Parlak M. Changes of microbial flora and wound colonization in burned patients. Burns 2004; 30: 357-61.
11. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27: 887-92.
12. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996; 15: 281-5.
13. Bonten MJ, Bergmans DC, Speijer H, Stobberingh EE. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control. Am. J. Crit. Care Med 1999; 160: 1212-9.
14. Takesue Y, Yokoyama T, Akagi S, et al. Changes in the intestinal flora after the administration of prophylactic antibiotics to patients undergoing a gastrectomy. Surg. Today 2002; 32: 581-6.
15. National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. American J infection control 1998; 26: 522-33.
16. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6: 428-42.
17. Kolleff MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-62.
18. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 2005; 41: 848-54.
19. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 2005; 49: 1306-11.
20. Bisbe J, Gatell JM, Puig J. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev. Infect. Dis 1988; 10: 629-35.
21. Hancock REW, Brinkman FS. Function of pseudomonas porins in uptake and efflux. Annu. Rev. Microbiol. 2002; 56: 17-38.
22. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical microbiology reviews 2009; 22: 582-610.
23. Dimatatac EL, Alejandria MM, Montalban C, Pineda C, Ang C, Delino R. Clinical outcomes and costs of care of antibiotic resistant Pseudomonas aeruginosa infections. Philipp. J. Microbiol Infect. Dis. 2003; 32: 159-67.
24. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrobial Agents Chemotherap 2010; 54: 969-76.
25. Sanders CC, Sanders WE. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J. Infect. Dis 1986; 154: 792-800.
26. Colom K, Fdz-Aranguiz A, Suinaga E, Cisterna R. Emergence of resistance to β-lactam agents in Pseudomonas aeruginosa with group I β-lactamases in Spain. Eur J Clin Microbiol Infect Dis 1995; 14: 964-71.
27. Livermore DM. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 2046-8.
28. Livermore DM, Yang YJ. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis 1987; 155: 775-82.
29. Masuda N, Gotoh N, Ishii C, Sakagawa E, Ohya S, Nishino T. Interplay between chromosomal β-lactamase and the MexABOprM efflux system in intrinsic resistance to β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 400-2.
30. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrobial Agents Chemotherap 2004; 48: 3086-92.
31. Gates ML, Sanders CC, Goering RV, Sanders WE, Jr. Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1986; 30: 453-7.
32. Sanders CC, Gates ML, Sanders WE, Jr. Heterogeneity of class I β-lactamase expression in clinical isolates of Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 1988; 32: 1893-5.
33. Wolter DJ, Hanson ND, Lister PD. AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump. Antimicrob Agents Chemother 2005; 49: 4763-6.
34. Labia R, Morand A, Peduzzi J. Timentin and beta-lactamases. J antimicrobial chemotherapy 1986; 17 Suppl C: 17-26.
35. Lindberg F, Lindquist S, Normark S. Genetic basis of induction and overproduction of chromosomal class I beta-lactamase in nonfastidious gram-negative bacilli. Reviews of infectious diseases 1988; 10: 782-5.
36. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999; 43: 882-9.
37. Stobberingh EE. Induction of chromosomal beta-lactamases by different concentrations of clavulanic acid in combination with ticarcillin. J antimicrobial chemotherapy 1988; 21: 9-16.
38. Weber DA, Sanders CC. Diverse potential of beta-lactamase inhibitors to induce class I enzymes. Antimicrobial Agents Chemotherap 1990; 34: 156-8.
39. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed Class I β-lactamases. J antimicrobial chemotherapy 1990; 25: 199-208.
40. Eron LJ, Goldenberg RI, Poretz DM, Park CH. Piperacillin therapy for Pseudomonas infections. Southern medical journal 1983; 76: 859-62.
41. Gribble MJ, Chow AW, Naiman SC, et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillinaminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrobial Agents Chemotherap 1983; 24: 388-93.
42. Jimenez-Lucho VE, Saravolatz LD, Medeiros AA, Pohlod D. Failure of therapy in pseudomonas endocarditis: selection of resistant mutants. J infectious diseases 1986; 154: 64-8.
43. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A. Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrobial Agents Chemotherap 2005; 49: 4733-8.
44. Letendre ED, Mantha R, Turgeon PL. Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. J antimicrobial chemotherapy 1988; 22: 557-62.
45. Masterton RG, Garner PJ, Harrison NA, Rainford DJ. Timentin resistance. Lancet 1987; 2: 975-6.
46. Scully BE, Ores CN, Prince AS, Neu HC. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Reviews of infectious diseases 1985; 7 Suppl 4: S669-74.
47. Sanders CC, Sanders WE, Jr. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Reviews of infectious diseases 1983; 5: 639-48.
48. Sanders WE, Jr., Sanders CC. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Reviews of infectious diseases 1988; 10: 830-8.
49. Barnaud G, Labia R, Raskine L, Sanson-Le Pors MJ, Philippon A, Arlet G. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS microbiology letters 2001; 195: 185-90.
50. Mammeri H, Galleni M, Nordmann P. Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC betalactamases in Escherichia coli. Antimicrobial Agents Chemotherap 2009; 53: 323-6.
51. Mammeri H, Nordmann P, Berkani A, Eb F. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli. FEMS microbiology letters 2008; 282: 238-40.
52. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate. Antimicrobial Agents Chemotherap 2004; 48: 716-20.
53. Matsumura N, Minami S, Mitsuhashi S. Sequences of homologous beta-lactamases from clinical isolates of Serratia marcescens with different substrate specificities. Antimicrobial Agents Chemotherap 1998; 42: 176-9.
54. Rodriguez-Martinez JM, Poirel L, Nordmann P. Extendedspectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2009; 53: 1766-71.
55. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2009; 53: 4783-8.
56. Datta N, Richmond MH. The purification and properties of a penicillinase whose synthesis is mediated by an R-factor in Escherichia coli. The Biochemical journal 1966; 98: 204-9.
57. Matthew M. Plasmid-mediated β-lactamases of Gram-negative bacteria: properties and distribution. J antimicrobial chemotherapy 1979; 5: 349-58.
58. Jacoby GA, Matthew M. The distribution of β-lactamase genes on plasmids found in Pseudomonas. Plasmid 1979; 2: 41-7.
59. Brun-Buisson C, Legrand P, Rauss A, et al. Intestinal decontamination for control of nosocomial multiresistant gramnegative bacilli. Study of an outbreak in an intensive care unit. Annals of internal medicine 1989; 110: 873-81.
60. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broadspectrum cephalosporins. Antimicrobial Agents Chemotherap 1985; 28: 302-7.
61. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable Resistance to Cefotaxime, Cefoxitin, Cefamandole and Cefuroxime in Clinical Isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
62. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51, table of contents.
63. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clinical microbiology reviews 2005; 18: 657-86.
64. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 1996; 40: 2488-93.
65. Al Naiemi N, Duim B, Bart A. A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. Journal of medical microbiology 2006; 55: 1607-8.
66. Dubois V, Arpin C, Noury P, Quentin C. Clinical strain of Pseudomonas aeruginosa carrying a bla(TEM-21) gene located on a chromosomal interrupted TnA type transposon. Antimicrobial Agents Chemotherap 2002; 46: 3624-6.
67. Marchandin H, Jean-Pierre H, De Champs C, et al. Production of a TEM-24 plasmid-mediated extended-spectrum β-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2000; 44: 213-6.
68. Poirel L, Ronco E, Naas T, Nordmann P. Extended-spectrum β-lactamase TEM-4 in Pseudomonas aeruginosa. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 1999; 5: 651-2.
69. Chanawong A, M'Zali FH, Heritage J, Lulitanond A, Hawkey PM. SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum β-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J antimicrobial chemotherapy 2001; 48: 839-52.
70. Naas T, Philippon L, Poirel L, Ronco E, Nordmann P. An SHVderived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 1999; 43: 1281-4.
71. Al Naiemi NA, Duim B, Savelkoul PH, et al. Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. Journal of clinical microbiology 2005; 43: 4862-4.
72. Poirel L, Lebessi E, Castro M, Fevre C, Foustoukou M, Nordmann P. Nosocomial outbreak of extended-spectrum β-lactamase SHV-5-producing isolates of Pseudomonas aeruginosa in Athens, Greece. Antimicrobial Agents Chemotherap 2004; 48: 2277-9.
73. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrobial Agents Chemotherap 2004; 48: 1-14.
74. Humeniuk C, Arlet G, Gautier V, Grimont P, Labia R, Philippon A. β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrobial Agents Chemotherap 2002; 46: 3045-9.
75. Celenza G, Pellegrini C, Caccamo M, Segatore B, Amicosante G, Perilli M. Spread of bla(CTX-M-type) and bla(PER-2) β-lactamase genes in clinical isolates from Bolivian hospitals. J antimicrobial chemotherapy 2006; 57: 975-8.
76. Picao RC, Poirel L, Gales AC, Nordmann P. Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2009; 53: 2225-6.
77. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 1993; 37: 962-9.
78. Naas T, Poirel L, Karim A, Nordmann P. Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum β-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS microbiology letters 1999; 176: 411-9.
79. Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. Nosocomial spread of the integron-located VEB-1-like cassette encoding an extended-pectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2002; 34: 603-11.
80. Poirel L, Rotimi VO, Mokaddas EM, Karim A, Nordmann P. VEB-1-like extended-spectrum β-lactamases in Pseudomonas aeruginosa, Kuwait. Emerging infectious diseases 2001; 7: 468-70.
81. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron In52 from Klebsiella pneumoniae. Antimicrobial Agents Chemotherap 2000; 44: 622-32.
82. Dubois V, Poirel L, Marie C, Arpin C, Nordmann P, Quentin C. Molecular characterization of a novel class 1 integron containing bla(GES-1) and a fused product of aac3-Ib/aac6'-Ib' gene cassettes in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2002; 46: 638-45.
83. Kotsakis SD, Papagiannitsis CC, Tzelepi E, Legakis NJ, Miriagou V, Tzouvelekis LS. GES-13, a β-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2010; 54: 1331-3.
84. Mavroidi A, Tzelepi E, Tsakris A, Miriagou V, Sofianou D, Tzouvelekis LS. An integron-associated β-lactamase (IBC-2) from Pseudomonas aeruginosa is a variant of the extended-spectrum beta-lactamase IBC-1. J antimicrobial chemotherapy 2001; 48: 627-30.
85. Poirel L, Brinas L, Fortineau N, Nordmann P. Integron-encoded GES-type extended-spectrum β-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2005; 49: 3593-7.
86. Poirel L, Brinas L, Verlinde A, Ide L, Nordmann P. BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2005; 49: 3743-8.
87. Poirel L, Docquier JD, De Luca F, et al. BEL-2, an extendedspectrum β-lactamase with increased activity toward expandedspectrum cephalosporins in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2010; 54: 533-5.
88. Tian GB, Adams-Haduch JM, Bogdanovich T, Wang HN, Doi Y. PME-1, an extended-spectrum β-lactamase identified in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2011; 55: 2710-3.
89. Paisley JW, Washington JA, 2nd. Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli. Antimicrobial Agents Chemotherap 1978; 14: 224-7.
90. Thomson KS, Weber DA, Sanders CC, Sanders WE, Jr. β-lactamase production in members of the family Enterobacteriaceae and resistance to β-lactam-enzyme inhibitor combinations. Antimicrobial Agents Chemotherap 1990; 34: 622-7.
91. Sanders CC, Iaconis JP, Bodey GP, Samonis G. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrobial Agents Chemotherap 1988; 32: 1365-9.
92. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrobial Agents Chemotherap 2010; 54: 24-38.
93. Hall LM, Livermore DM, Gur D, Akova M, Akalin HE. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 1993; 37: 1637-44.
94. Juan C, Mulet X, Zamorano L, Alberti S, Perez JL, Oliver A. Detection of the novel extended-spectrum β-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. Antimicrobial Agents Chemotherap 2009; 53: 5288-90.
95. Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. J antimicrobial chemotherapy 2006; 57: 373-83.
96. Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48: 2043-8.
97. Sevillano E, Gallego L, Garcia-Lobo JM. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. Pathologie-biologie 2009; 57: 493-5.
98. Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrobial Agents Chemotherap 2000; 44: 1556-61.
99. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007; 20: 440-58, table of contents.
100. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J antimicrobial chemotherapy 2007; 60: 470-82.
101. Labuschagne Cde J, Weldhagen GF, Ehlers MM, Dove MG. Emergence of class 1 integron-associated GES-5 and GES-5-like extended-spectrum beta-lactamases in clinical isolates of Pseudomonas aeruginosa in South Africa. Int J Antimicrobial Agents 2008; 31: 527-30.
102. Picao RC, Poirel L, Gales AC, Nordmann P. Diversity of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. Antimicrobial Agents Chemotherap 2009; 53: 3908-13.
103. Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum β-lactamase GES-2 in South Africa. J antimicrobial chemotherapy 2002; 49: 561-5.
104. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A β-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrobial Agents Chemotherap 2001; 45: 2598-603.
105. Wang C, Cai P, Chang D, Mi Z. A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum β-lactamase. J antimicrobial chemotherapy 2006; 57: 1261-2.
106. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother 2007; 51: 1553-5.
107. Wolter DJ, Khalaf N, Robledo IE, et al. Surveillance of Carbapenem Resistant Pseudomonas aeruginosa from Puerto Rico Medical Center Hospitals: Dissemination of KPC and IMP-18 β-lactamases. Antimicrob Agents Chemother 2009.
108. Akpaka PE, Swanston WH, Ihemere HN, et al. Emergence of KPCproducing Pseudomonas aeruginosa in Trinidad and Tobago. Journal of clinical microbiology 2009; 47: 2670-1.
109. Ge C, Wei Z, Jiang Y, Shen P, Yu Y, Li L. Identification of KPC-2-producing Pseudomonas aeruginosa isolates in China. J antimicrobial chemotherap 2011; 66: 1184-6.
110. Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. Emergence of KPC-producing Pseudomonas aeruginosa in the United States. Antimicrobial Agents Chemotherap 2010; 54: 3072.
111. Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 2009; 53: 557-62.
112. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-betalactamases: the quiet before the storm? Clinical microbiology reviews 2005; 18: 306-25.
113. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147-51.
114. Hancock RE, Brinkman FS. Function of pseudomonas porins in uptake and efflux. Annu Rev Microbiol 2002; 56: 17-38.
115. Trias J, Nikaido H. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J Biol Chem 1990; 265: 15680-4.
116. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990; 34: 52-7.
117. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43: 424-7.
118. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
119. Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis 1988; 10: 892-8.
120. Wolter DJ, Hanson ND, Lister PD. Discordance Between Imipenem (IPM) Resistance and oprD Expression in a Pseudomonas aeruginosa (PA) Overexpressing mexEF-oprN (EFN), abstr. C1-1061. In Program and abstracts of the 48rd Interscience Conference on Antimicrobial Agents Chemotherap. American Society for Microbiology, Washington, D.C. 2008.
121. Perez FJ, Gimeno C, Navarro D, Garcia-de-Lomas J. Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel. Chemotherapy 1996; 42: 210-14.
122. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. Journal of antibiotics 2006; 59: 220-8.
123. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. Journal of antimicrobial chemotherapy 2005; 55: 944-9.
124. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrobial Agents Chemotherap 1998; 42: 94-9.
125. Riera E, Cabot G, Mulet X, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrobial Chemotherapy 2011.
126. Gotoh N, Wakebe H, Nishino T. Ultrastructural aspects of fragility of Pseudomonas aeruginosa outer membrane devoid of protein F. FEMS microbiology letters 1989; 50: 51-3.
127. Gotoh N, Wakebe H, Yoshihara E, Nakae T, Nishino T. Role of protein F in maintaining structural integrity of the Pseudomonas aeruginosa outer membrane. Journal of bacteriology 1989; 171: 983-90.
128. Rawling EG, Brinkman FS, Hancock RE. Roles of the carboxyterminal half of Pseudomonas aeruginosa major outer membrane protein OprF in cell shape, growth in low-osmolarity medium, and peptidoglycan association. J Bacteriol 1998; 180: 3556-62.
129. Nestorovich EM, Sugawara E, Nikaido H, Bezrukov SM. Pseudomonas aeruginosa porin OprF: properties of the channel. J biological chemistry 2006; 281: 16230-7.
130. Azghani AO, Idell S, Bains M, Hancock RE. Pseudomonas aeruginosa outer membrane protein F is an adhesin in bacterial binding to lung epithelial cells in culture. Microb Pathog 2002; 33: 109-14.
131. Yoon SS, Hennigan RF, Hilliard GM, et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 2002; 3: 593-603.
132. Piddock LJ, Hall MC, Bellido F, Bains M, Hancock RE. A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 1057-61.
133. Woodruff WA, Hancock RE. Construction and characterization of Pseudomonas aeruginosa protein F-deficient mutants after in vitro and in vivo insertion mutagenesis of the cloned gene. J Bacteriol 1988; 170: 2592-8.
134. Woodruff WA, Hancock RE. Pseudomonas aeruginosa outer membrane protein F: structural role and relationship to the Escherichia coli OmpA protein. J Bacteriol 1989; 171: 3304-9.
135. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000; 406: 959-64.
136. Pos KM, Schiefner A, Seeger MA, Diederichs K. Crystallographic analysis of AcrB. FEBS letters 2004; 564: 333-9.
137. Yu EW, McDermott G, Zgurskaya HI, Nikaido H, Koshland DE, Jr. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 2003; 300: 976-80.
138. Middlemiss JK, Poole K. Differential impact of MexB mutations on substrate selectivity of the MexAB-OprM multidrug efflux pump of Pseudomonas aeruginosa. J Bacteriol 2004; 186: 1258-69.
139. Yu EW, Aires JR, Nikaido H. AcrB multidrug efflux pump of Escherichia coli: composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. J Bacteriol 2003; 185: 5657-64.
140. Mao W, Warren MS, Black DS, et al. On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol Microbiol 2002; 46: 889-901.
141. Yu EW, Aires JR, McDermott G, Nikaido H. A periplasmic drugbinding site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. Journal of bacteriology 2005; 187: 6804-15.
142. Bohnert JA, Schuster S, Seeger MA, Fahnrich E, Pos KM, Kern WV. Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB. Journal of bacteriology 2008; 190: 8225-9.
143. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006; 443: 173-9.
144. Pages JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gramnegative bacteria. Trends in molecular medicine 2005; 11: 382-9.
145. Aires JR, Kohler T, Nikaido H, Plesiat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 1999; 43: 2624-8.
146. Chuanchuen R, Murata T, Gotoh N, Schweizer HP. Substratedependent utilization of OprM or OpmH by the Pseudomonas aeruginosa MexJK efflux pump. Antimicrob Agents Chemother 2005; 49: 2133-6.
147. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 415-7.
148. Murata T, Gotoh N, Nishino T. Characterization of outer membrane efflux proteins OpmE, OpmD and OpmB of Pseudomonas aeruginosa: molecular cloning and development of specific antisera. FEMS Microbiol Lett 2002; 217: 57-63.
149. Li XZ, Zhang L, Srikumar R, Poole K. β-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42: 399-403.
150. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 2001; 1: 59-71.
151. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 1948-53.
152. Morita Y, Kimura N, Mima T, Mizushima T, Tsuchiya T. Roles of MexXY-and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAO1. J Gen Appl Microbiol 2001; 47: 27-32.
153. Maseda H, Sawada I, Saito K, Uchiyama H, Nakae T, Nomura N. Enhancement of the mexAB-oprM efflux pump expression by a quorum-sensing autoinducer and its cancellation by a regulator, MexT, of the mexEF-oprN efflux pump operon in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004; 48: 1320-8.
154. Sawada I, Maseda H, Nakae T, Uchiyama H, Nomura N. A quorum-sensing autoinducer enhances the mexAB-oprM effluxpump expression without the MexR-mediated regulation in Pseudomonas aeruginosa. Microbiol Immunol 2004; 48: 435-9.
155. Evans K, Adewoye L, Poole K. MexR repressor of the mexABoprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region. J Bacteriol 2001; 183: 807-12.
156. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs DE, Bianco N. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother 1996; 40: 2021-8.
157. Morita Y, Cao L, Gould VC, Avison MB, Poole K. nalD encodes a second repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa. J Bacteriol 2006; 188: 8649-54.
158. Adewoye L, Sutherland A, Srikumar R, Poole K. The mexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. J Bacteriol 2002; 184: 4308-12.
159. Saito K, Akama H, Yoshihara E, Nakae T. Mutations affecting DNA-binding activity of the MexR repressor of mexR-mexAmexB-oprM operon expression. J Bacteriol 2003; 185: 6195-8.
160. Cao L, Srikumar R, Poole K. MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Mol Microbiol 2004; 53: 1423-36.
161. Daigle DM, Cao L, Fraud S, et al. Protein modulator of multidrug efflux gene expression in Pseudomonas aeruginosa. J Bacteriol 2007; 189: 5441-51.
162. Wilke MS, Heller M, Creagh AL, et al. The crystal structure of MexR from Pseudomonas aeruginosa in complex with its antirepressor ArmR. Proc Natl Acad Sci U S A 2008; 105: 14832-7.
163. Srikumar R, Paul CJ, Poole K. Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 2000; 182: 1410-4.
164. Masuda N, Gotoh N, Ohya S, Nishino T. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 909-13.
165. Poole K, Gotoh N, Tsujimoto H, et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996; 21: 713-24.
166. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-7.
167. Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy 2002; 8: 371-3.
168. Gotoh N, Tsujimoto H, Tsuda M, et al. Characterization of the MexC-MexD-OprJ multidrug efflux system in βmexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42: 1938-43.
169. Morita Y, Komori Y, Mima T, Kuroda T, Mizushima T, Tsuchiya T. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from Pseudomonas aeruginosa PAO1: MexCD-OprJ is an inducible pump. FEMS Microbiol Lett 2001; 202: 139-43.
170. Srikumar R, Li XZ, Poole K. Inner membrane efflux components are responsible for β-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa. J Bacteriol 1997; 179: 7875-81.
171. Shiba T, Ishiguro K, Takemoto N, Koibuchi H, Sugimoto K. Purification and characterization of the Pseudomonas aeruginosa NfxB protein, the negative regulator of the nfxB gene. J Bacteriol 1995; 177: 5872-7.
172. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Effluxmediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-8.
173. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44: 710-2.
174. Hocquet D, Nordmann P, El Garch F, Cabanne L, Plesiat P. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1347-51.
175. Baum EZ, Crespo-Carbone SM, Morrow BJ, et al. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2009; 53: 2785-90.
176. Queenan AM, Shang W, Bush K, Flamm RK. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrobial Agents Chemotherap 2010; 54: 4092-7.
177. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 2242-6.
178. Jeannot K, Sobel ML, El Garch F, Poole K, Plesiat P. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction. J Bacteriol 2005; 187: 5341-6.
179. Matsuo Y, Eda S, Gotoh N, Yoshihara E, Nakae T. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA. FEMS Microbiol Lett 2004; 238: 23-8.
180. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plesiat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 2004; 48: 1797-802.
181. Muller C, Plesiat P, Jeannot K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2011; 55: 1211-21.
182. Adewoye L, Sutherland A, Srikumar R, Poole K. The mexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. Journal of Bacteriology 2002; 184: 4308-4312.
183. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plesiat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrobial Agents Chemotherap 2004; 48: 1797-1802.
184. Pai H, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanims in Pseudomonas aeruginosa clinical isolates. Antimicrobial Agents Chemotherap 2001; 45: 480-484.
185. Sobel ML, Hocquet D, Cao L, Plesiat P, Poole K. Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2005; 49: 1782-1786.
186. Wolter DJ, Acquazzino D, Goering RV, Sammut P, Khalaf N, Hanson ND. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. Clinical Infectious Diseases 2008; 46:e137-141.
187. Hocquet D, Nordmann P, El Garch F, Cabanne L, Plesiat P. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 2006; 50: 1347-1351.
188. Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrobial Agents Chemotherap 2003; 48: 3202-3207.
189. Vogne C, Aires JR, Bailly C, Hocquet D, Plesiat P. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrobial Agents Chemotherap 2004; 48: 1676-1680.
190. Wolter DJ, Smith-Moland E, Goering RV, Hanson ND, Lister PD. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagnostic Microbiology and Infectious Disease 2004; 50: 43-50.
191. Laohavaleeson S, Lolans K, Quinn JP, Kuti JL, Nicolau DP. Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles. Infection and drug resistance 2008; 1: 51-5.
192. Jeannot K, Elsen S, Kohler T, Attree I, van Delden C, Plesiat P. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother 2008; 52: 2455-62.
193. Reinhardt A, Kohler T, Wood P, et al. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrobial Agents Chemotherap 2007; 51: 1341-50.
194. Campo Esquisabel AB, Rodriguez MC, et al. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2011.
195. Linares JF, Lopez JA, Camafeita E, Albar JP, Rojo F, Martinez JL. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. Journal of bacteriology 2005; 187: 1384-91.
196. Sanchez P, Linares JF, Ruiz-Diez B, et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J antimicrobial chemotherapy 2002; 50: 657-64.
197. Stickland HG, Davenport PW, Lilley KS, Griffin JL, Welch M. Mutation of nfxB causes global changes in the physiology and metabolism of Pseudomonas aeruginosa. Journal of proteome research 2010; 9: 2957-67.
198. Pai H, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45: 480-4.
199. Tomas M, Doumith M, Warner M, et al. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrobial Agents Chemotherap 2010; 54: 2219-24.
200. Wolter DJ, Acquazzino D, Goering RV, Sammut P, Khalaf N, Hanson ND. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. Clin Infect Dis 2008; 46: e137-41.
201. Pumbwe L, Piddock LJ. Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 2861-4.
202. Hocquet D, Roussel-Delvallez M, Cavallo JD, Plesiat P. MexABOprM-and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrobial Agents Chemotherap 2007; 51: 1582-3.
203. Cabot G, Ocampo-Sosa AA, Tubau F, et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobial Agents Chemotherap 2011; 55: 1906-11.
204. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrobial Agents Chemotherap 2006; 50: 1633-41.
205. Hocquet D, Berthelot P, Roussel-Delvallez M, et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrobial Agents Chemotherap 2007; 51: 3531-6.
206. Wolter DJ, Smith-Moland E, Goering RV, Hanson ND, Lister PD. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn Microbiol Infect Dis 2004; 50: 43-50.
207. Xavier DE, Picao RC, Girardello R, Fehlberg LC, Gales AC. Efflux pumps expression and its association with porin downregulation and β-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil. BMC microbiology 2010; 10: 217.
208. Maniati M, Ikonomidis A, Mantzana P, Daponte A, Maniatis AN, Pournaras S. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD. J antimicrobial chemotherapy 2007; 60: 132-5.
209. Vettoretti L, Floret N, Hocquet D, et al. Emergence of extensivedrug-resistant Pseudomonas aeruginosa in a French university hospital. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 2009; 28: 1217-22.
210. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL. Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to β-lactam antibiotics. Antimicrobial Agents Chemotherap 2010; 54: 4159-67.
211. Dotsch A, Becker T, Pommerenke C, Magnowska Z, Jansch L, Haussler S. Genomewide identification of genetic determinants of antimicrobial drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 2522-31.
212. Peng X, Xu C, Ren H, Lin X, Wu L, Wang S. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of Pseudomonas aeruginosa responding to ampicilin, kanamycin, and tetracycline resistance. Journal of proteome research 2005; 4: 2257-65.
213. Liberati NT, Urbach JM, Miyata S, et al. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proceedings of the National Academy of Sciences of the USA 2006; 103: 2833-8.
214. Godfrey AJ, Hatlelid L, Bryan LE. Correlation between lipopolysaccharide structure and permeability resistance in β-lactam-resistant Pseudomonas aeruginosa. Antimicrobial Agents Chemotherap 1984; 26: 181-6.
215. Leying HJ, Buscher KH, Cullmann W, Then RL. Lipopolysaccharide alterations responsible for combined quinolone and β-lactam resistance in Pseudomonas aeruginosa. Chemotherapy 1992; 38: 82-91.
216. Kropinski AM, Kuzio J, Angus BL, Hancock RE. Chemical and chromatographic analysis of lipopolysaccharide from an antibioticsupersusceptible mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1982; 21: 310-9.